Trials / Recruiting
RecruitingNCT07269899
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
A Phase I Study Evaluating the Preliminary Efficacy and Safety of WTX212A Injection as Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, investigator-initiated clinical study (IIT) designed to evaluate the preliminary efficacy, safety, tolerability, immunogenicity, and pharmacokinetic (PK) characteristics of WTX212A Injection in patients with advanced solid tumors.
Detailed description
This is a single-arm, open-label, investigator-initiated clinical study (IIT) designed to evaluate the preliminary efficacy, safety, tolerability, immunogenicity, and pharmacokinetic (PK) characteristics of WTX212A Injection in patients with advanced solid tumors. The study is divided into two phases: an initial exploratory phase and an expansion phase. The study includes two cohorts: Cohort A (WTX212A monotherapy) and Cohort B (WTX212A in combination with radiotherapy)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WTX212A injection | Erythrocyte-αPD-1 Antibody Conjugates |
| RADIATION | radiotherapy | Radiotherapy will be administered sequentially, with WTX212A treatment starting within one week after the completion of radiotherapy |
Timeline
- Start date
- 2025-11-25
- Primary completion
- 2027-02-28
- Completion
- 2027-08-30
- First posted
- 2025-12-08
- Last updated
- 2025-12-08
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07269899. Inclusion in this directory is not an endorsement.